argenx SE (A1RG34) - Total Assets
Based on the latest financial reports, argenx SE (A1RG34) holds total assets worth R$8.68 Billion BRL as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
argenx SE - Total Assets Trend (2021–2025)
This chart illustrates how argenx SE's total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
argenx SE - Asset Composition Analysis
Current Asset Composition (December 2025)
argenx SE's total assets of R$8.68 Billion consist of 79.5% current assets and 20.5% non-current assets.
| Asset Category | Amount (BRL) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | R$0.00 | 40.2% |
| Accounts Receivable | R$1.49 Billion | 17.2% |
| Inventory | R$473.53 Million | 5.5% |
| Property, Plant & Equipment | R$0.00 | 0.0% |
| Intangible Assets | R$272.10 Million | 3.1% |
| Goodwill | R$0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how argenx SE's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: argenx SE's current assets represent 79.5% of total assets in 2025, a decrease from 89.2% in 2021.
- Cash Position: Cash and equivalents constituted 40.2% of total assets in 2025, down from 46.8% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, a decrease from 6.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 17.2% of total assets.
argenx SE Competitors by Total Assets
Key competitors of argenx SE based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
ACRO Biomedical Co., Ltd.
TWO:6748
|
Taiwan | NT$607.52 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
argenx SE - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.23 | 7.29 | 8.53 |
| Quick Ratio | 4.87 | 6.68 | 7.88 |
| Cash Ratio | 0.00 | 2.23 | 2.82 |
| Working Capital | R$5.58 Billion | R$4.21 Billion | R$3.76 Billion |
argenx SE - Advanced Valuation Insights
This section examines the relationship between argenx SE's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.88 |
| Latest Market Cap to Assets Ratio | 5.80 |
| Asset Growth Rate (YoY) | 40.0% |
| Total Assets | R$8.68 Billion |
| Market Capitalization | $50.32 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values argenx SE's assets at a significant premium (5.80x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: argenx SE's assets grew by 40.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for argenx SE (2021–2025)
The table below shows the annual total assets of argenx SE from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | R$8.68 Billion | +39.99% |
| 2024-12-31 | R$6.20 Billion | +36.55% |
| 2023-12-31 | R$4.54 Billion | +44.93% |
| 2022-12-31 | R$3.13 Billion | +9.96% |
| 2021-12-31 | R$2.85 Billion | -- |
About argenx SE
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develo… Read more